TESARO (TSRO) Posts Smaller Q2 Loss on Higher Revs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to TESARO (TSRO) Posts Smaller Q2 Loss on Higher Revs

Tesaro Announces Second-Quarter 2016 Operating Results

August 4, 2016 4:06 PM EDT

Positive Phase 3 data reported by TESARO and ENGOT from the NOVA trial of niraparib in a broad population of patients with platinum-sensitive, recurrent ovarian cancerPre-launch planning underway to support four potential product launches in 2017 across U.S. and EuropeExpansion of TESARO European commercial organization now ongoing  Immuno-oncology programs continue to advance, with candidates targeting TIM-3 and PD-1 now in Phase 1 clinical trials; combination trials targeted for 2017Cash and cash equivalents totaled approximately $320 million as of June 30, 2016; additional $409 million raised in a follow-on offering completed in... More